Canagliflozin shares common mTOR and MAPK signaling mechanisms with other lifespan extension treatments

A new paper by the ITP researchers:

Long-lived mouse models and treatments that extend lifespan, such as Rapamycin, acarbose and 17α- -estradiol, lead to reduction in mTORC1 activity, declines in cap-dependent translation and increases in cap-independent translation. In addition, these treatments reduce the MEK-ERK-MNK (ERK1–2) signaling cascade, leading to reduction in eIF4E phosphorylation, which also regulates mRNA translation. Here, we report that Canagliflozin, a drug that extends lifespan only in male mice reduces mTORC1 and ERK1–2 signaling in male mice only. The data suggest reduction in mTORC1 and ERK pathways are common mechanisms shared by both genetic and pharmacological models of slowed aging in mice. Our data also reveal a significant sexual dimorphism in the ERK1–2 signaling pathway which might help to explain why some drugs can extend lifespan in males but have no effects in female mice.

Paywalled Paper:


I always thought it would be interesting to see if we can extend male life expectancy to match that of females… Or even go beyond!

The full paper

Canagliflozin Effects in Intracellular Signaling SM.pdf (721.8 KB)